A phase I clinical trial of recombinant human IL‐15 infusion evaluated in patients with metastatic melanoma and renal cell cancer demonstrated significant changes in NK, γδ and CD8 memory T cells.27 This evidence concerns the gene CD8A and renal cell adenocarcinoma.